Answers are grounded in this paper and cite their sources.
Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) is now frequently used in early clinical trial assessment of antiangiogenic and vascular disrupting compounds. Evidence of drug efficacy and dose-dependent response has been demonstrated with some angiogenesis inhibitors. This review highlights the critical issues that influence T(1)-weighted DCE-MRI data acquisition and analysis, identifies important areas for future development and reviews the clinical trial findings to date.
No takes yet. Share an insight, caveat, or question.
O’Connor et al. (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: